Search - tctmd.com

Displaying 861 - 880 of 1134

Sort: Relevancy | Date

News Daily News

RECLOSE-3: Shifting Clopidogrel Nonresponders to Prasugrel Lowers Mortality After PCI

Yael L. Maxwell

September 18, 2015

News Conference News ESC 2015

ESC Congress 2015: Presentations Sift Clinical Wheat From Chaff

September 09, 2015

News Industry News

Bristol-Myers Squibb and Pfizer Enroll First Patient in Phase 4 AUGUSTUS Trial to Evaluate Safety of Eliquis (apixaban) in Nonvalvular Atrial Fibrillation Patients with a Recent ACS or Undrgoing PCI

September 09, 2015

News Industry News

US FDA Approves Expanded Indication For Brilinta To Include Long-term Use In Patients With a History of Heart Attack

September 03, 2015

News Conference News ESC 2015

MATRIX Antithrombin: Bivalirudin Fails to Reduce Net Adverse Events vs Heparin in ACS Patients Undergoing PCI

Yael L. Maxwell

September 02, 2015

News Conference News ESC 2015

NSAIDs Plus Anticoagulants a Bad Combination

Caitlin E. Cox

September 01, 2015

News Conference News ESC 2015

Ezetimibe Benefits Diabetics, and Does Not Increase Risk of New-Onset Diabetes

Yael L. Maxwell

September 01, 2015

News Conference News ESC 2015

DAPT Analysis Eases Concerns Over Slightly Higher Death Rate Seen With Extended Thienopyridine Use

Caitlin E. Cox

September 01, 2015

News Conference News ESC 2015

OPTIDUAL: No Clear Need to Lengthen DAPT to 4 Years After DES

Caitlin E. Cox

August 31, 2015

News Conference News ESC 2015

Meta-analysis: Long-Term DAPT Beneficial for Patients With History of MI

Yael L. Maxwell

August 31, 2015

News Conference News ESC 2015

Analyses Suggest Prasugrel Causes No Excess Bleeding in Stable CAD Patients

Caitlin E. Cox

August 31, 2015

News Industry News

FDA approves Repatha to treat certain patients with high cholesterol

August 28, 2015

News Daily News

CAD Location May Influence Need for Prolonged DAPT Post-PCI

Caitlin E. Cox

August 24, 2015

News Industry News

New Analyses from the IMPROVE-IT Outcomes Study of VYTORIN® (ezetimibe and simvastatin) and the TECOS Cardiovascular Safety Trial of JANUVIA® Will Be Presented at the European Society of Cardiology

August 20, 2015

News Daily News

Novel Antisense Inhibitor Cuts High Triglyceride Levels

August 13, 2015

News Daily News

BARI 2D: Increased Risk Factor Control in Patients With Type 2 Diabetes Ups Survival

Yael L. Maxwell

August 12, 2015

News Daily News

Triple Therapy Yields No Thrombotic Benefit, More Bleeding in Older PCI Patients With A-fib

August 04, 2015

News Daily News

斑块消退证据对于联合使用他汀类药物与依泽替米贝的病例提出了支持

L.A. McKeown

July 29, 2015

News Daily News

Subestudio BASKET-PROVE: Los SLF son Mejores que los SMD en Pacientes Ancianos con Arterias Grandes

Yael L. Maxwell

July 29, 2015

News Daily News

La Evidencia de la Regresión de la Placa Avala el Uso Combinado de Ezetimibe+Estatinas

L.A. McKeown

July 29, 2015

Advertisement

RECLOSE-3: Shifting Clopidogrel Nonresponders to Prasugrel Lowers Mortality After PCI

ESC Congress 2015: Presentations Sift Clinical Wheat From Chaff

Bristol-Myers Squibb and Pfizer Enroll First Patient in Phase 4 AUGUSTUS Trial to Evaluate Safety of Eliquis (apixaban) in Nonvalvular Atrial Fibrillation Patients with a Recent ACS or Undrgoing PCI

US FDA Approves Expanded Indication For Brilinta To Include Long-term Use In Patients With a History of Heart Attack

MATRIX Antithrombin: Bivalirudin Fails to Reduce Net Adverse Events vs Heparin in ACS Patients Undergoing PCI

NSAIDs Plus Anticoagulants a Bad Combination

Ezetimibe Benefits Diabetics, and Does Not Increase Risk of New-Onset Diabetes

DAPT Analysis Eases Concerns Over Slightly Higher Death Rate Seen With Extended Thienopyridine Use

OPTIDUAL: No Clear Need to Lengthen DAPT to 4 Years After DES

Meta-analysis: Long-Term DAPT Beneficial for Patients With History of MI

Analyses Suggest Prasugrel Causes No Excess Bleeding in Stable CAD Patients

FDA approves Repatha to treat certain patients with high cholesterol

CAD Location May Influence Need for Prolonged DAPT Post-PCI

New Analyses from the IMPROVE-IT Outcomes Study of VYTORIN® (ezetimibe and simvastatin) and the TECOS Cardiovascular Safety Trial of JANUVIA® Will Be Presented at the European Society of Cardiology

Novel Antisense Inhibitor Cuts High Triglyceride Levels

BARI 2D: Increased Risk Factor Control in Patients With Type 2 Diabetes Ups Survival

Triple Therapy Yields No Thrombotic Benefit, More Bleeding in Older PCI Patients With A-fib

斑块消退证据对于联合使用他汀类药物与依泽替米贝的病例提出了支持

Subestudio BASKET-PROVE: Los SLF son Mejores que los SMD en Pacientes Ancianos con Arterias Grandes

La Evidencia de la Regresión de la Placa Avala el Uso Combinado de Ezetimibe+Estatinas

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content